<DOC>
	<DOCNO>NCT02670044</DOCNO>
	<brief_summary>The primary objective study assess safety tolerability well preliminary efficacy venetoclax combination cobimetinib , venetoclax combination idasanutlin patient &gt; /= 60 year age relapse refractory acute myeloid leukemia ( R/R ) AML eligible cytotoxic therapy .</brief_summary>
	<brief_title>A Study Venetoclax Combination With Cobimetinib Venetoclax Combination With Idasanutlin Patients Aged &gt; /= 60 Years With Relapsed Refractory Acute Myeloid Leukemia Who Are Not Eligible Cytotoxic Therapy</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<criteria>Age &gt; /= 60 year Histological confirmation relapse refractory AML prior antileukemic therapy WHO Classification Not eligible cytotoxic therapy Ineligible allogeneic stem cell transplant Life expectancy least 12 week Eastern Cooperative Oncology Group ( ECOG ) Performance Status 02 Adequate liver renal function Patients acute promyelocytic leukemia ( FrenchAmericanBritish [ FAB ] class M3 AML ) Known active central nervous system ( CNS ) involvement AML study entry Prior exposure Bcl2 inhibitor , murine double minute 2 ( MDM2 ) antagonists prior exposure experimental treatment target Raf , mitogenactivated protein kinase ( MEK ) , mitogenactivated protein kinase ( MAPK ) RAS/RAF/MEK/ERK MAPK pathway Positive hepatitis C virus ( HCV ) , hepatitis B surface antigen ( HBsAg ) know history HIV , malignancy , active infection cardiovascular disease ( CVs ) Received strong cytochrome ( CYP ) 3A inhibitor , moderate CYP3A inhibitor , strong CYP3A inducer moderate CYP3A inducer within 7 day prior initiation study treatment History symptomatic Clostridium difficile infection within 1 month prior dose Additional phase specific exclusion criterion : Phase Ib Dose Escalation Arm A ( Venetoclax Cobimetinib ) History evidence retinal pathology ophthalmologic examination consider risk factor neurosensory retinal detachment/central serous chorioretinopathy ( CSCR ) , retinal vein occlusion ( RVO ) , neovascular macular degeneration Left ventricular ejection fraction ( LVEF ) institutional low limit normal ( LLN ) 50 % , whichever low Phase Ib DoseEscalation Arm B ( Venetoclax Idasanutlin ) : Received follow within 7 day prior initiation study treatment : Strong CYP2C8 inhibitor CYP2C8 substrates OATP1B1/3 substrates Received follow within 14 day prior initiation study treatment : * Strong CYP2C8 inducer Received hormonal therapy ( apart luteinizing hormone release hormone agonist/antagonist prostate cancer hormone replacement therapy ) within 2 week prior first dose study treatment History liver cirrhosis radiologic , clinical laboratory data , biopsy despite normal liver function test Phase II Expansion Arm A Arm B : Received follow within 7 day prior initiation study treatment : Strong CYP2C8 inhibitor CYP2C8 substrates OATP1B1/3 substrates Received follow within 14 day prior initiation study treatment : * Strong CYP2C8 inducer History evidence retinal pathology ophthalmologic examination consider risk factor neurosensory retinal detachment/CSCR , RVO , neovascular macular degeneration LVEF institutional LLN 50 % , whichever low Received hormonal therapy ( apart luteinizing hormone release hormone agonist/antagonist prostate cancer hormone replacement therapy ) within 2 week prior first dose study treatment History liver cirrhosis radiologic , clinical laboratory data , biopsy despite normal liver function test</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>